Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Talaris Therapeutics Inc.
With
Northwestern University
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) and living donor kidney transplant.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure
Patient is receiving first renal transplant
Patient is receiving a renal transplant only
The crossmatch is negative between donor and recipient
Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of initiating total body irradiation (TBI) and agree to use reliable contraception for 1 year following transplant
Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF)
No evidence of donor-specific antibody presently or historically
You may not be if
Clinically active bacterial, fungal, viral or parasitic infection
Pregnancy
Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant
Previous radiation therapy at a dose which would preclude TBI
Positive crossmatch between donor and recipient
Evidence for immunologic memory against donor
BMI \>35 or \<18
Re-transplant
Positive serologies for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV
